Regeneron Pharmaceuticals and Sanofi announced positive results from multiple Phase 3 trials of their drug Dupixent, demonstrating its effectiveness in treating chronic skin conditions like chronic spontaneous urticaria (CSU) and bullous pemphigoid. These findings could lead to expanded approval for Dupixent to treat a wider range of skin conditions.